Previous close | 5.18 |
Open | 5.18 |
Bid | 5.18 x 575900 |
Ask | 5.19 x 611100 |
Day's range | 5.14 - 5.24 |
52-week range | 5.14 - 7.64 |
Volume | |
Avg. volume | 1,171,014 |
Market cap | 4.244B |
Beta (5Y monthly) | 1.23 |
PE ratio (TTM) | 13.34 |
EPS (TTM) | 0.39 |
Earnings date | N/A |
Forward dividend & yield | 0.34 (6.47%) |
Ex-dividend date | 17 Mar 2022 |
1y target est | 8.13 |
Fletcher Building Limited ( NZSE:FBU ), might not be a large cap stock, but it received a lot of attention from a...
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon Topline Data from Phase 1 Trial Expected in the Second Half of 2022 CARLSBAD, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that its Investigational New Drug Application (IND) for its lead candidate, DT-216, for the treatment of Friedreich ataxia (FA), was cleared by the U.S. Food an
The big shareholder groups in Fletcher Building Limited ( NZSE:FBU ) have power over the company. Institutions will...